(Q38087695)

28 August 2017

Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach (English)

1 reference

28 August 2017

0 references

Karen Rowland Yeo

1

1 reference

28 August 2017

Masoud Jamei

series ordinal

2

1 reference

28 August 2017

Amin Rostami-Hodjegan

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 March 2013

1 reference

Expert Review of Clinical Pharmacology

28 August 2017

1 reference

28 August 2017

6

1 reference

28 August 2017

143-157

1 reference

28 August 2017

2

1 reference

Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

28 August 2017

1 reference

Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology

21 January 2018

1 reference

A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recogn

21 January 2018

1 reference

Physiologically-based pharmacokinetics in drug development and regulatory science

21 January 2018

1 reference

Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review

21 January 2018

1 reference

Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo

21 January 2018

1 reference

Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development.

21 January 2018

1 reference

Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole

21 January 2018

1 reference

Membrane transporters in drug development

21 January 2018

1 reference

Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation

21 January 2018

1 reference

Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned?

21 January 2018

1 reference

Reduction of metformin renal tubular secretion by cimetidine in man

21 January 2018

1 reference

Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells

21 January 2018

1 reference

Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

21 January 2018

1 reference

Role of OATP transporters in the disposition of drugs

21 January 2018

1 reference

effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers

21 January 2018

1 reference

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake

21 January 2018

1 reference

CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide

21 January 2018

1 reference

Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin

21 January 2018

1 reference

The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects

21 January 2018

1 reference

Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide

21 January 2018

1 reference

Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

21 January 2018

1 reference

Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport

21 January 2018

1 reference

Theoretical considerations on quantitative prediction of drug-drug interactions

21 January 2018

1 reference

Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites

21 January 2018

1 reference

Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition

21 January 2018

1 reference

Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction

21 January 2018

1 reference

The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes

21 January 2018

1 reference

Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction

21 January 2018

1 reference

General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information

21 January 2018

1 reference

Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions

21 January 2018

1 reference

Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay

21 January 2018

1 reference

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions

21 January 2018

1 reference

The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions

21 January 2018

1 reference

Maraviroc: in vitro assessment of drug-drug interaction potential

21 January 2018

1 reference

Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator

21 January 2018

1 reference

Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction

21 January 2018

1 reference

Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction

21 January 2018

1 reference

Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism

21 January 2018

1 reference

Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug

21 January 2018

1 reference

Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs

21 January 2018

1 reference

Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions.

21 January 2018

1 reference

In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions

21 January 2018

1 reference

Transporter-mediated drug--drug interactions involving OATP substrates: predictions based on in vitro inhibition studies.

21 January 2018

1 reference

Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions.

21 January 2018

1 reference

Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance

21 January 2018

1 reference

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

21 January 2018

1 reference

Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors

21 January 2018

1 reference

A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes

21 January 2018

1 reference

Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability

21 January 2018

1 reference

Changes in liver volume from birth to adulthood: a meta-analysis.

21 January 2018

1 reference

Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children

21 January 2018

1 reference

Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences

21 January 2018

1 reference

Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus.

21 January 2018

1 reference

Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.

21 January 2018

1 reference

Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance

21 January 2018

1 reference

A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance

21 January 2018

1 reference

Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis

21 January 2018

1 reference

Modeling and predicting drug pharmacokinetics in patients with renal impairment.

21 January 2018

1 reference

Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation.

21 January 2018

1 reference

Protein binding predictions in infants

21 January 2018

1 reference

Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs.

21 January 2018

1 reference

Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model.

21 January 2018

1 reference

Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on th

21 January 2018

1 reference

Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors

21 January 2018

1 reference

A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro

21 January 2018

1 reference

Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models

21 January 2018

1 reference

Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.

21 January 2018

1 reference

The effects of dose staggering on metabolic drug-drug interactions.

21 January 2018

1 reference

Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study

21 January 2018

1 reference

Whole-body physiologically based pharmacokinetic models

21 January 2018

1 reference

Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation

21 January 2018

1 reference

Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling

21 January 2018

1 reference

Physiologically based pharmacokinetics (PBPK).

21 January 2018

1 reference

Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.

21 January 2018

1 reference

Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?

21 January 2018

1 reference

Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.

21 January 2018

1 reference

Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events

21 January 2018

1 reference

Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies

21 January 2018

1 reference

From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example

21 January 2018

1 reference

PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism

21 January 2018

1 reference

Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans

21 January 2018

1 reference

Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.

21 January 2018

1 reference

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data

21 January 2018

1 reference

Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities.

21 January 2018

1 reference

Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine

21 January 2018

1 reference

Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science

21 January 2018

1 reference

Markov chain Monte Carlo methods in biostatistics.

21 January 2018

1 reference

Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor

21 January 2018

1 reference

Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers

21 January 2018

1 reference

Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics

21 January 2018

1 reference

Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine

21 January 2018

1 reference

Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator

21 January 2018

1 reference

In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude

21 January 2018

1 reference

Insulinotropic meglitinide analogues

21 January 2018

1 reference

Rifampin decreases the plasma concentrations and effects of repaglinide

21 January 2018

1 reference

Cyclosporine markedly raises the plasma concentrations of repaglinide

21 January 2018

1 reference

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECP.13.4

1 reference

28 August 2017

1 reference